Inactive Instrument

BioAdaptives, Inc. Share Price Other OTC

Equities

BDPT

US09072U1079

Food Processing

Sales 2022 0.02 1.43 Sales 2023 0.03 2.38 Capitalization 448K 37.34M
Net income 2022 - 0 Net income 2023 - 0 EV / Sales 2022 3,01,65,231 x
Net Debt 2022 367K 30.57M Net Debt 2023 268K 22.38M EV / Sales 2023 2,50,75,337 x
P/E ratio 2022
-0.07 x
P/E ratio 2023
-0.39 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 99.77%
More Fundamentals * Assessed data
Dynamic Chart
BioAdaptives, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Bioadaptives, Inc. Announces Naturacomplete?, an All-In-One Supplement to Optimize Its Ai-Based FYO Obesity Management System CI
BioAdaptives Announces Signing of a New Distributor?s Agreement for AI Body Composition Measuring App and New Weight Management System CI
BioAdaptives Inc. Announces the Development of PROTEINnMORETM CI
BioAdaptives Announces the Development of VeganHepPlusTM Liver Supplement Formula CI
BioAdaptives, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
BioAdaptives, Inc. Highlights Continued Success of Popular LUNG ARMOR System as US Enters Flu Season CI
BioAdaptives, Inc. Announces Nationwide Launch of Lung Fortress Natural Supplement CI
BioAdaptives, Inc. Commences Development of A New Supplement for Women?S Health CI
BioAdaptives, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
BioAdaptives, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
BioAdaptives, Inc. Announces the Appointment of David Allen to its Board of Directors CI
BioAdaptives, Inc. Signs Non-Exclusive Marketing Agreement with World Wellness, LLC CI
BioAdaptives, Inc. Announces the Appointment of Dr. Yaguang Liu to its Board of Directors CI
BioAdaptives, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
More news
Managers TitleAgeSince
Chief Executive Officer 83 15/18/15
Director of Finance/CFO 82 11/19/11
Chief Operating Officer 78 31/21/31
Members of the board TitleAgeSince
Chief Executive Officer 83 15/18/15
Director of Finance/CFO 82 11/19/11
Chief Operating Officer 78 31/21/31
More insiders
BioAdaptives, Inc. manufactures and distributes natural plant and algal-based products that improve health and wellness for humans and animals, with an emphasis on optimizing pain relief, antiviral activity, and immune system defense; resistance to stress; endurance; recovery from injury, illness, and exercise; and anti-aging properties. Its products include dietary supplements using natural ingredients and proprietary methods of optimizing the availability of nutrients in foods and beverages. Its product line for humans includes PluriPain, PrimiLungs, SleepEZ, MindNMemory, Cell Rejuven and ProteinNMore. It also markets the Lung Flute and PrimiLungs products in its Lung Armor packaging, emphasizing the anti-viral properties of the nutraceutical and general respiratory health benefits from use of the device. Its animal products include an Equine All-in-One and Equine All-In-One Plus formulation, which it markets to trainers, horse owners and boarding stables, and a Canine All-in-One.
More about the company